interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Milsaperidone

Generic competition · all medicines · read 12 November 2026

Is there a generic of Milsaperidone, and who makes it?

Milsaperidone appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Milsaperidone1 dosage-form group in the Orange Book
0generic makers listed
  1. Milsaperidone appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Bysanti. No generic is listed as marketed.

20202025203020352040204501brand 2026data datePatent 10570453 listed to expire 28 March 2028Patent 9157121 listed to expire 5 April 2030Patent 10563259 listed to expire 24 July 2030Patent 12606869 listed to expire 22 September 2030Patent 8999638 listed to expire 28 October 2030Patent 9074255 listed to expire 17 December 2030Patent 9072742 listed to expire 16 January 2031Patent 9074256 listed to expire 10 February 2031Patent 9074254 listed to expire 28 December 2031Patent 12478619 listed to expire 31 May 2044Exclusivity NCE to 20 February 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 20 February 2031Exclusivity NCE Bysanti
  • 28 March 2028Patent 10570453
  • 5 April 2030Patent 9157121
  • 24 July 2030Patent 10563259
  • 22 September 2030Patent 12606869
  • 28 October 2030Patent 8999638
  • 17 December 2030Patent 9074255
  • 16 January 2031Patent 9072742
  • 10 February 2031Patent 9074256

2 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.